Skip to main content
. 2020 Dec 16;65(1):e01103-20. doi: 10.1128/AAC.01103-20

FIG 1.

FIG 1

Time- and dose-dependent effects of shCD5 infusion in C. albicans-infected CD1 mice. (A) Survival percentage over time of CD1 mice infected with C. albicans (3 × 103 CFU/g, i.v.) and treated (i.v.) with a single 1.25-mg/kg dose of HSA (+18 h, n = 29) or shCD5 (+9 h, n = 15; +18 h, n = 29; +48 h, n = 7) at the indicated time points (hours) postinfection. (B) Survival percentage of CD1 mice infected with C. albicans (3 × 103 CFU/g, i.v.) and treated (i.v.) with single-dose HSA (1.25 mg/kg, n = 18) or shCD5 (0.625 mg/kg, n = 11; 1.25 mg/kg, n = 6; 2.5 mg/kg, n = 6) 18 h later. (C) Spleen and kidney fungal burden (CFU/g) at 48 h and 72 h postinfection of CD1 mice with C. albicans (3 × 103 CFU/g, i.v.) and treated (i.v.) with a single 1.25-mg/kg dose of HSA (n = 7) or shCD5 (n = 7) 18 h later. Statistical differences between groups were analyzed by log rank (Mantel-Cox) test (A and B) and Mann-Whitney test (C).*, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001.